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METHODS: This study used administrative claims data
to identify continuously enrolled patients using insulin
between 1/1/98 and 12/31/99. During a six-month iden-
tiﬁcation period, patients receiving one or more prescrip-
tions for lispro were categorized as lispro patients.
Non-lispro patients were then matched to lispro patients
using a Propensity Score (PS) derived from baseline char-
acteristics. The PS model included variables such as age,
gender, comorbidities, oral hypoglycemic use, dominant
physician specialty, health plan location and baseline
costs. After 1 :1 matching, 12 months of follow-up cost
and utilization data were then compared using
unmatched t-tests.
RESULTS: Of 11,443 patients, 3,341 (29.2%) had at
least one prescription for lispro insulin, while the remain-
ing 8,102 (70.8%) had at least one regular (non-lispro)
insulin prescription. At baseline, lispro patients tended to
be younger, were more often Type 1 with a history of
insulin use, had fewer comorbidities, visited endocrinol-
ogists over family practice physicians and had lower total
costs. PS balancing assured that only the 1,832 most
appropriate patients of each type were then used in out-
comes comparisons. Lispro patients had signiﬁcantly
higher average ofﬁce visits (p = 0.0022) and pharmacy
prescriptions (p = 0.0165) but lower inpatient hospital
visits (p = 0.0028) compared to non-lispro patients. Cost
results were similar with lispro insulin patients having sig-
niﬁcantly higher average ofﬁce visit costs (p = 0.0237) and
pharmacy costs (p < 0.0001) but lower inpatient hospital
costs (p = 0.0227). Total costs were not signiﬁcantly 
different (p = 0.5266).
CONCLUSIONS: Lispro insulin and non-lispro regular
insulin patients did not incur signiﬁcantly different total
costs. While lispro patients had higher pharmacy and
ofﬁce visit costs, they did not incur higher total medical
costs. More intensive ambulatory care in such chronic
disease patients does not appear to be associated with
higher overall medical costs.
DIABETES—Quality of Life Presentations
PDB12
FACTORS PREDICTING SELF-RATED HEALTH
AND PATIENT SATISFACTION IN A MANAGED
CARE DIABETES POPULATION
Nau DP, Kumar RN
University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: To determine the relationship of demo-
graphics, severity of illness and quality of care measures
with general health perception (GHP) and patient satis-
faction (PS) levels among managed care diabetes patients.
METHODS: The sample included 300 adult diabetes
patients enrolled in an IPA-model HMO. All data were
collected through surveys and medical claims. Survey data
from July 1999 were merged with medical and pharmacy
claims data from July 1998 through June 1999. Our
analysis consisted of two multiple regression models with
GHP (100 point transformed scale, higher score = better
health) and PS (9 point scale, higher score = greater sat-
isfaction) being the dependent variables, respectively. Pre-
dictor variables in both models included: demographics
(age, gender, education, income), severity of illness
(insulin use, duration of diabetes), number of comorbidi-
ties, receipt of foot and eye exams, diabetes education,
lipid tests, microalbumin tests, frequency of self-
monitoring of blood glucose, and the frequency of tests
for HbA1c and blood glucose.
RESULTS: Mean (SD) for GHP and PS scores were 49.8
(25.0) and 7.8 (1.8), respectively. The R2 for model 1
(GHP) and model 2 (PS) were 0.20 and 0.10, respectively.
Signiﬁcant predictors (p < 0.05) of GHP included comor-
bidities (beta = -0.11), income (beta = 0.26), and HbA1c
tests (beta = 0.19). Thus, higher GHP was associated with
having fewer comorbidities, higher income and more fre-
quent testing of HbA1c in the prior year. Signiﬁcant pre-
dictors of PS included comorbidities (beta = -0.15), foot
exams (beta = 0.16), and diabetes education (beta = 0.16).
Thus, higher satisfaction was associated with fewer
comorbidities, receipt of a foot exam from any healthcare
provider, and participation in a diabetes education
program.
CONCLUSION: When controlling for demographics,
comorbidities and severity of illness, those patients who
received more frequent HbA1c monitoring reported
higher self-rated health, and patients who received foot
exams and diabetes education were more satisﬁed with
the care they received for diabetes.
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OBJECTIVES: New oral antihyperglycemic drugs
(OADs) have been introduced in recent years, and dia-
betes treatment guidelines are increasingly suggesting that
insulin be used for type-2 diabetes only when other ther-
apies are ineffective. This study evaluates the resulting
impacts on trends in insulin mono and combination 
therapies for type-2 diabetic patients from 1997–2000.
METHODS: Commercially insured patients who had one
or more diabetes diagnoses or drugs are selected from
over 3 million employees, retirees, and dependents in each
of the years 1997–2000 of The MEDSTAT Group Mar-
ketScan database. Patients likely to have type-1 diabetes
are identiﬁed and removed from the database. Descrip-
tive analyses compare the percentages of type-2 diabetes
patients treated with insulin monotherapy and speciﬁc
combination therapies in each of the four years. Statisti-
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cal analyses are conducted to assess the signiﬁcance of
trends.
RESULTS: Up to 155,000 type-2 diabetes patients are
identiﬁed in each year. Insulin was used by 21.6% in
1997, decreasing to 20.3% in 2000. During the same
period, the use of insulin-alone declined from 12.6% to
9.9%, while the use of insulin and OADs in the same year
increased from 9.0% to 10.4%. Patients receiving insulin,
compared to patients treated with OADs or no drug
therapy, were more likely to have signiﬁcant diabetic
comorbidities (54.4% vs. 26.1% and 21.5%), and more
doctor visits per year (9.2 vs.7.4 and 6.8).
CONCLUSIONS: It appears that the use of insulin
therapy for treating type 2 diabetes patients has declined
slightly over the past four years (1997–2000), possibly in
response to the introduction of new oral antihyper-
glycemic drugs and the widespread promotion of treat-
ment guidelines. It is likely that the use of insulin
combination therapies has increased, while the use of
insulin monotherapy has decreased over the same time
period.
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PATIENT’S PERSPECTIVE OF HYPOGLYCEMIA
AS AN ADVERSE EFFECT OF ORAL
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OBJECTIVE: To assess patient perspective on hypo-
glycemia in patients with type 2 diabetes taking oral
hypoglycemic agents (OHAs).
METHODS: A questionnaire was developed to explore
the subjects’ perception and knowledge of hypoglycemia,
including frequency and severity of symptoms. We also
assessed the potential relationship of hypoglycemia to
OHAs. Thirty-one study subjects with type 2 diabetes and
at least 30 years of age responded to advertisements to
participate in this study. Patients were distributed in three
groups according to age and previous experience 
of hypoglycemia: group 1: older patients with hypo-
glycemia experience, group 2: patients without previous
hypoglycemia and group 3: adults with previous hypo-
glycemia. Patients completed a questionnaire and then
took part in a moderated focus group.
RESULTS: Eight subjects in group 1 (mean age 66.4 ± 2.8
years old) and 12 patients in group 3 (mean age 52.7 ±
6.4 years old) reported experiencing hypoglycemia; while
12 patients in group 2 (mean age 56.8 ± 6.8 years old)
reported, “not experiencing hypoglycemia” in the past.
Patients completed the questionnaire and then partici-
pated in a moderated focus group. Less than 25% of
group 1 and 2 patients recognized the symptoms of hypo-
glycemia. Approximately 27% of patients in group 2
experienced these symptoms but none recognized they
were manifestations of hypoglycemia and 18% reported
that they experienced trembling very often or always.
None of the subjects connected these symptoms with their
antidiabetic medications. All patients in group 1 seemed
to be surprised that OHAs have side effects. Approxi-
mately 25% of patients gave a wrong deﬁnition of hypo-
glycemia in their questionnaires.
CONCLUSIONS: There seems to be a large information
gap about hypoglycemia. Patient and provider education
is needed to help patients to understand what hypo-
glycemia is or recognize the symptoms of hypoglycemia.
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OBJECTIVES: The objective of this study was to deter-
mine if routinely collected administrative claims data
could be used to effectively predict what segment of a
population of patients with type 2 diabetes mellitus (type
2 DM) would progress to insulin as part of their drug
regimen.
METHODS: To determine the time until a patient with
type 2 DM starts insulin, deﬁned as survival time, we used
the PHREG procedure of SAS. This procedure uses Cox’s
proportional hazards model in order to estimate survival
functions for diabetic patients. Based on the number of
medications in the patients’ regimen, eleven models were
developed to predict the number of patients in a cohort
expected to start insulin therapy over the two-year study
period. The models were also used to identify the patients
most likely to start insulin therapy and to estimate their
probability. Split sample design was used to gauge the
predictive ability of the models.
RESULTS: In the monotherapy cohort model, the average
of the absolute difference between the predicted and
actual number of patients starting insulin each month was
0.965, with the maximum error for any month being 4.1
patients (an average of 27 patients started insulin per
month). 27.03% and 24.12% of the patients that went
on insulin within six months or two years respectively
were in the top 10% in terms of risk. In comparison,
3.3% and 3.53% of the patients that went on insulin
within six months or two years respectively were found
to be in the bottom 10% in terms of risk.
CONCLUSIONS: This study demonstrates that survival
models can be used to predict and identify patients with
type 2 DM who will require insulin as part of their treat-
ment regimen. As a result, it is possible to develop tools
based on these models that can be used by practitioners
to assist in patient care.
